T. Rowe Price Associates
BBIO icon

T. Rowe Price Associates’s BridgeBio Pharma BBIO Stock Holding History

T. Rowe Price Associates’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282M Sell
3,801,655
-27,091
-0.7% -$1.96M 0.03% 370
2025
Q4 		$293M Buy
3,828,746
+2,261,181
+144% +$148M 0.03% 359
2025
Q3 		$81.4M Buy
1,567,565
+606,349
+63% +$29.6M 0.01% 668
2025
Q2 		$41.5M Sell
961,216
-203,751
-17% -$7.41M ﹤0.01% 774
2025
Q1 		$40.3M Buy
1,164,967
+173,729
+18% +$5.86M 0.01% 785
2024
Q4 		$27.2M Buy
991,238
+180,773
+22% +$4.67M ﹤0.01% 918
2024
Q3 		$20.6M Sell
810,465
-14,353
-2% -$377K ﹤0.01% 986
2024
Q2 		$20.9M Buy
824,818
+20,862
+3% +$570K ﹤0.01% 957
2024
Q1 		$24.9M Buy
803,956
+145,594
+22% +$4.95M ﹤0.01% 923
2023
Q4 		$26.6M Buy
658,362
+596,386
+962% +$17.9M ﹤0.01% 880
2023
Q3 		$1.64M Buy
61,976
+2,220
+4% +$63K ﹤0.01% 1554
2023
Q2 		$1.03M Buy
59,756
+4,555
+8% +$68.5K ﹤0.01% 1796
2023
Q1 		$916K Sell
55,201
-11,321
-17% -$132K ﹤0.01% 1831
2022
Q4 		$507K Sell
66,522
-16,764
-20% -$161K ﹤0.01% 2127
2022
Q3 		$828K Sell
83,286
-6,911
-8% -$71.8K ﹤0.01% 1860
2022
Q2 		$819K Buy
90,197
+23,973
+36% +$201K ﹤0.01% 1983
2022
Q1 		$672K Buy
66,224
+24,238
+58% +$249K ﹤0.01% 2209
2021
Q4 		$700K Sell
41,986
-2,507
-6% -$106K ﹤0.01% 2221
2021
Q3 		$2.08M Sell
44,493
-498,672
-92% -$26.7M ﹤0.01% 1708
2021
Q2 		$33.1M Sell
543,165
-62,825
-10% -$3.59M ﹤0.01% 1173
2021
Q1 		$37.3M Buy
605,990
+575,776
+1,906% +$37.7M ﹤0.01% 1101
2020
Q4 		$2.15M Buy
30,214
+3,141
+12% +$152K ﹤0.01% 1615
2020
Q3 		$1.02M Buy
27,073
+9,118
+51% +$287K ﹤0.01% 1788
2020
Q2 		$586K Buy
17,955
+244
+1% +$7.43K ﹤0.01% 1991
2020
Q1 		$514K Buy
+17,711
New +$549K ﹤0.01% 1983

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's BBIO Position: Q1 2026 in Review

T. Rowe Price Associates reduced its BridgeBio Pharma (BBIO) stake by 0.71% in Q1 2026, selling an estimated $1.96M and leaving 3,801,655 shares worth $282M. The position accounts for 0.03% of the portfolio, ranked #370.

T. Rowe Price Associates first reported a position in BBIO in Q1 2020 and has held it in 25 quarters since. The position peaked at $293M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • T. Rowe Price Associates held 3,801,655 shares of BridgeBio Pharma worth $282M as of Q1 2026.
  • T. Rowe Price Associates sold 27,091 BridgeBio Pharma shares in Q1 2026, an estimated $1.96M.
  • BridgeBio Pharma made up 0.03% of T. Rowe Price Associates's portfolio in Q1 2026, its #370 holding.
  • T. Rowe Price Associates first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 25 quarters since.
  • T. Rowe Price Associates's BridgeBio Pharma position peaked at $293M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.